세계의 혈액 스크리닝 시장 예측(-2028년) : 제품별, 기술별, 최종사용자별, 지역별

Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028

US $ 4,950 ￦ 6,881,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,245,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,330,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,903,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 혈액 스크리닝 시장 규모는 2023년 24억 달러에서 2028년까지 34억 달러에 달하며, 예측 기간 중 CAGR로 7.2%의 성장이 예측됩니다.

시장의 성장은 주로 헌혈에 대한 요구의 증가, 전 세계에서 헌혈의 증가, 계속 증가하는 감염증에 의해 촉진되고 있습니다. 그러나 혈액 스크리닝 기기와 키트의 높은 가격과 기술자의 부족이 시장의 성장을 방해할 가능성이 높습니다.

조사 범위
조사 대상년	2021-2028년
기준년	2022년
예측 기간	2023-2028년
단위	달러
부문	제품·서비스, 기술, 최종사용자, 지역
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중근동 아프리카

"예측 기간 중 제품·서비스별로는 시약·키트 부문이 시장에서 가장 높은 성장률을 차지했습니다."

2022년, 시약·키트 부문이 시장에서 가장 높은 성장률을 차지했습니다. 시장 성장의 주요 요인은 수혈과 헌혈의 증가입니다. 또한 혈액 스크리닝 기술의 진보나 수술 건수의 증가가 이 부문의 성장을 자극하고 있습니다.

"혈액은행 부문이 가장 높은 CAGR을 차지했습니다."

2022년, 혈액은행 부문이 가장 높은 성장률을 차지했습니다. 이것은 장기 이식 수술 건수의 증가, 혈액 안전성에 관한 의식의 향상에 기인하고 있습니다.

"아시아태평양 : 가장 급성장하고 있는 지역 시장"

예측 기간에 가장 CAGR이 높은 것은 아시아태평양입니다. 1인당 소득의 증가, 아시아태평양 국가에서 지방으로의 사립 병원 진출, 아시아태평양 국가에서 노년 인구의 증가( 및 만성질환의 유행), 이 지역의 고성장 시장 존재 등이 의료 지출의 증가에 기여하고 있습니다. 또한 이 지역의 양호한 규제 상황과 낮은 인건비도 시장 성장을 촉진할 것으로 예측됩니다.

세계의 혈액 스크리닝 시장에 대해 조사분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 제공하고 있습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

• 혈액 스크리닝 시장의 개요
• 혈액 스크리닝 시장 : 제품·서비스별(2023년·2028년)
• 혈액 스크리닝 시장 : 기술별(2023년·2028년)
• 혈액 스크리닝 시장 : 최종사용자별(2023년·2028년)
• 혈액 스크리닝 시장 : 지역적 성장 기회

제5장 시장의 개요

• 서론
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
  • 과제
• 가격 분석
  • 가격 모델 분석
  • 평균 판매 가격의 동향
  • 혈액 스크리닝 제품 평균 판매 가격 : 주요 기업별
• 특허 분석
  • 핵산 증폭 기술의 특허 분석
  • 혈액 스크리닝 시장 : 주요 특허 리스트
• 밸류체인 분석
• 공급망 분석
• 에코시스템 분석
• Porter's Five Forces 분석
• 규제 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동
• 무역 분석
• 기술 분석
• 주요 컨퍼런스와 이벤트
• PESTLE 분석
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 주요 이해관계자와 구입 기준
• 사례 연구 분석

제6장 혈액 스크리닝 시장 : 제품·서비스별

• 서론
• 시약·키트
  • NAT 시약·키트
  • ELISA 시약·키트
  • 기타 시약·키트
• 기구
  • 렌탈 구입
  • 일괄구입
• 소프트웨어·서비스

제7장 혈액 스크리닝 시장 : 기술별

• 서론
• 핵산 증폭 검사(NAT)
  • 전사 매개 증폭(TMA)
  • 실시간 중합효소 연쇄 반응(RT-PCR)
• 혈청학/면역분석법
  • 화학발광면역측정(CLIA)
  • 형광 면역분석법(FIA)
  • 비색 면역분석법/ELISA(CI/ELISA)
• 신속 검사
• 웨스턴 블롯 어세이
• 차세대 시퀀싱(NGS)

제8장 혈액 스크리닝 시장 : 최종사용자별

• 서론
• 혈액은행
• 병원

제9장 혈액 스크리닝 시장 : 지역별

• 서론
• 북미
  • 북미의 불황의 영향
  • 미국
  • 캐나다
• 유럽
  • 유럽의 불황의 영향
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 불황의 영향
  • 중국
  • 일본
  • 인도
  • 호주
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 불황의 영향
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카

제10장 경쟁 구도

• 개요
• 주요 기업의 전략
• 매출 점유율 분석
• 시장 점유율 분석
• 기업의 평가 매트릭스
• 스타트업/중소기업 평가 매트릭스(2022년)
• 경쟁 벤치마킹
• 경쟁 시나리오

제11장 기업 개요

• 주요 기업
  • F. HOFFMANN-LA ROCHE LTD.
  • GRIFOLS, S.A.
  • ABBOTT LABORATORIES
  • BIO-RAD LABORATORIES, INC.
  • DIASORIN
  • BIOMERIEUX
  • BD
  • DANAHER(BECKMAN COULTER, INC.)
  • HOLOGIC, INC.
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC, INC.
• 기타 기업
  • ORTHO CLINICAL DIAGNOSTICS
  • MERCK KGAA
  • REVVITY(PART OF PERKINELMER INC.)
  • BIO-TECHNE
  • GFE
  • TRINITY BIOTECH
  • J. MITRA & CO. PVT. LTD.
  • MINDRAY
  • MACCURA BIOTECHNOLOGY CO., LTD.
  • IMMUCOR, INC.
  • CELLABS
  • ABNOVA CORPORATION
  • ENZO BIOCHEM, INC.
  • TULIP DIAGNOSTICS PVT. LTD.

제12장 부록

KSA

영문 목차

영문목차

The global blood screening market is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However high prices of Blood screening instruments and kits along with scarcity in technicians is likely to hamper the growth of Blood screening market.

Scope of the Report
Years Considered for the Study	2021-2028
Base Year	2022
Forecast Period	2023-2028
Units Considered	USD
Segments	Product & Service Technology End User Region
Regions covered	North America, Europe, APAC, LATAM, MEA

"The reagents & kits segment accounted for the highest growth rate in the blood screening market, by product & service, during the forecast period."

The blood screening market is segmented into reagents & kits, instruments, and software & services based on product. In 2022, the reagents & kits segment accounted for the highest growth rate in the blood screening market. Market growth can largely be attributed to rising number of blood transfusions and blood donations. In addition, technological advancements in blood screening technologies and the increasing number of surgeries are stimulating the growth of this segment.

"Blood banks segment accounted for the highest CAGR."

Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2022, the blood banks segment accounted for the highest growth rate. This can be attributed to the growing number of organ transplantation surgeries, and rising awareness about blood safety.

"Asia Pacific: The fastest-growing region blood screening market."

The global blood screening market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The highest CAGR is anticipated to be recorded over the forecast period in the Asia Pacific region. The rising per capita income, the expansion of private hospitals into rural areas in various APAC countries, the rising geriatric population in several APAC countries (coupled with the rising prevalence of chronic disorders), and the presence of high-growth markets in the region, among other factors, all contribute to rising healthcare spending. The favorable regulatory climate and low labor costs in this region are also anticipated to fuel market growth.

.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level (27%), Director-level (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)

Prominent companies include F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMerieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Research Coverage

This research report categorizes the Blood screening market by products & service, technology, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Blood screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Blood screening market. Competitive analysis of upcoming startups in the Blood screening market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall blood screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing number of blood donations, rising infectious diseases and growing technological advancements), restraints (Alternative Technologies), opportunities (Increasing Demand from Emerging Economies in APAC, Increasing collaboration between businesses, industry associations, and government awareness), and challenges (High cost of blood screening products) influencing the growth of the blood screening market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the blood screening market
• Market Development: Comprehensive information about lucrative markets - the report analyses the blood screening market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the blood screening market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMerieux (France), among others in blood screening market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 BLOOD SCREENING MARKET
  • 1.3.2 REGIONS COVERED
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 LIMITATIONS
• 1.7 STAKEHOLDERS
• 1.8 SUMMARY OF CHANGES
• 1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • FIGURE 1 BLOOD SCREENING MARKET: RESEARCH DESIGN METHODOLOGY
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3.2 TOP-DOWN APPROACH
  • FIGURE 6 BLOOD SCREENING MARKET: TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RISK ASSESSMENT
  • 2.8.1 RISK ASSESSMENT ANALYSIS
• 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

• FIGURE 8 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
• FIGURE 9 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
• FIGURE 10 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 11 BLOOD SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

• 4.1 BLOOD SCREENING MARKET OVERVIEW
  • FIGURE 12 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
• 4.2 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
  • FIGURE 13 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.3 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028
  • FIGURE 14 NUCLEIC ACID TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.4 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028
  • FIGURE 15 BLOOD BANKS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.5 BLOOD SCREENING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
  • FIGURE 16 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE FROM 2023 TO 2028

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 17 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing blood donations
    • 5.2.1.2 Rising prevalence of infectious diseases
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of blood screening technologies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising technological advancements
    • 5.2.3.2 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Usage of low-sensitivity screening tests
    • 5.2.4.2 Shortage of skilled laboratory technicians
• 5.3 PRICING ANALYSIS
  • 5.3.1 PRICING MODEL ANALYSIS
  • TABLE 1 INDICATIVE PRICING ANALYSIS FOR BLOOD SCREENING PRODUCTS
  • 5.3.2 AVERAGE SELLING PRICE TREND
  • TABLE 2 AVERAGE SELLING PRICE ANALYSIS OF BLOOD SCREENING PRODUCTS
  • 5.3.3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS, BY KEY PLAYER
  • TABLE 3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS
• 5.4 PATENT ANALYSIS
  • 5.4.1 PATENT ANALYSIS OF NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
  • 5.4.2 BLOOD SCREENING MARKET: LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 18 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
• 5.6 SUPPLY CHAIN ANALYSIS
  • FIGURE 19 BLOOD SCREENING MARKET: SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • FIGURE 20 BLOOD SCREENING MARKET: ECOSYSTEM MAP
  • 5.7.1 BLOOD SCREENING MARKET: ECOSYSTEM ROLE
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 4 BLOOD SCREENING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 BARGAINING POWER OF SUPPLIERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 REGULATORY LANDSCAPE
  • TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.1 NORTH AMERICA
    • 5.9.1.1 US
    • 5.9.1.2 Canada
  • 5.9.2 EUROPE
  • TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
  • 5.9.3 ASIA PACIFIC
    • 5.9.3.1 China
    • 5.9.3.2 Japan
  • TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.9.3.3 India
  • 5.9.4 LATIN AMERICA
    • 5.9.4.1 Brazil
  • 5.9.5 MIDDLE EAST
• 5.10 TRADE ANALYSIS
  • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
  • TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
• 5.11 TECHNOLOGY ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS
  • TABLE 13 BLOOD SCREENING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023 -2024)
• 5.13 PESTLE ANALYSIS
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.14.1 REVENUE SHIFT IN BLOOD SCREENING MARKET
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS
  • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS (%)
  • 5.15.2 BUYING CRITERIA
  • FIGURE 22 KEY BUYING CRITERIA FOR BLOOD SCREENING PRODUCTS
  • TABLE 15 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: OPTIMIZATION OF HBSAG QUANTITATIVE ELISA
  • 5.16.2 CASE STUDY 2: CLINICAL EFFICACY OF NAT WITH ELISA

6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 16 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
• 6.2 REAGENTS & KITS
  • TABLE 17 KEY PRODUCTS FOR REAGENTS & KITS
  • TABLE 18 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 19 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2.1 NAT REAGENTS & KITS
    • 6.2.1.1 High sensitivity to drive market
  • TABLE 20 KEY PRODUCTS FOR NAT REAGENTS & KITS
  • TABLE 21 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 22 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2.2 ELISA REAGENTS & KITS
    • 6.2.2.1 Ease of use and cost-effectiveness to drive market
  • TABLE 23 KEY PRODUCTS FOR ELISA REAGENTS & KITS
  • TABLE 24 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 25 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2.3 OTHER REAGENTS & KITS
  • TABLE 26 KEY PRODUCTS FOR OTHER REAGENTS & KITS
  • TABLE 27 BLOOD SCREENING MARKET FOR OTHER REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
• 6.3 INSTRUMENTS
  • TABLE 28 KEY PRODUCTS FOR INSTRUMENTS
  • TABLE 29 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 30 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • 6.3.1 RENTAL PURCHASE
    • 6.3.1.1 Reduced liability with limited financial losses to propel market
  • TABLE 31 BLOOD SCREENING MARKET FOR RENTAL PURCHASE INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3.2 OUTRIGHT PURCHASE
    • 6.3.2.1 Availability of government support to drive market
  • TABLE 32 BLOOD SCREENING MARKET FOR OUTRIGHT PURCHASE INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 RISING DEMAND ACROSS EMERGING ECONOMIES TO SUPPORT MARKET GROWTH
  • TABLE 33 KEY PRODUCTS FOR SOFTWARE & SERVICES
  • TABLE 34 BLOOD SCREENING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 BLOOD SCREENING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
  • TABLE 35 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
• 7.2 NUCLEIC ACID TESTS (NAT)
  • TABLE 36 KEY PRODUCTS IN NAT MARKET
  • TABLE 37 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 38 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA)
    • 7.2.1.1 High sensitivity to support market growth
  • TABLE 39 BLOOD SCREENING MARKET FOR TMA, BY REGION, 2021-2028 (USD MILLION)
  • 7.2.2 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR)
    • 7.2.2.1 Elimination of contamination risks to propel market
  • TABLE 40 BLOOD SCREENING MARKET FOR RT-PCR, BY REGION, 2021-2028 (USD MILLION)
• 7.3 SEROLOGY/IMMUNOASSAYS
  • TABLE 41 KEY PRODUCTS FOR SEROLOGY/IMMUNOASSAYS
  • TABLE 42 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 43 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • 7.3.1 CHEMILUMINESCENT IMMUNOASSAYS (CLIA)
    • 7.3.1.1 Ultra-sensitive and automated features to drive market
  • TABLE 44 BLOOD SCREENING MARKET FOR CHEMILUMINESCENT IMMUNOASSAYS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3.2 FLUORESCENT IMMUNOASSAYS (FIA)
    • 7.3.2.1 Rising demand for safe & stable reagents to propel market
  • TABLE 45 BLOOD SCREENING MARKET FOR FLUORESCENT IMMUNOASSAYS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3.3 COLORIMETRIC IMMUNOASSAYS/ELISA (CI/ELISA)
    • 7.3.3.1 Qualitative and quantitative antigen measurement for blood serum to drive market
  • TABLE 46 BLOOD SCREENING MARKT FOR COLORIMETRIC IMMUNOASSAYS/ELISA, BY REGION, 2021-2028 (USD MILLION)
• 7.4 RAPID TESTS
  • 7.4.1 HIGH EFFICIENCY IN POC DIAGNOSTICS TO PROPEL MARKET
  • TABLE 47 KEY PRODUCTS FOR RAPID TESTS
  • TABLE 48 BLOOD SCREENING MARKET FOR RAPID TESTS, BY REGION, 2021-2028 (USD MILLION)
• 7.5 WESTERN BLOT ASSAYS
  • 7.5.1 ABILITY TO DETECT RETROVIRUS ANTIBODIES TO DRIVE MARKET
  • TABLE 49 KEY PRODUCTS FOR WESTERN BLOT ASSAYS
  • TABLE 50 BLOOD SCREENING MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2021-2028 (USD MILLION)
• 7.6 NEXT-GENERATION SEQUENCING (NGS)
  • 7.6.1 EMERGING TECHNOLOGY FOR HIV TESTING TO SUPPORT MARKET GROWTH
  • TABLE 51 BLOOD SCREENING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)

8 BLOOD SCREENING MARKET, BY END USER

• 8.1 INTRODUCTION
  • TABLE 52 BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 8.2 BLOOD BANKS
  • 8.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • TABLE 53 BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION, 2021-2028 (USD MILLION)
• 8.3 HOSPITALS
  • 8.3.1 INCREASING SURGICAL PROCEDURES TO PROPEL MARKET
  • TABLE 54 BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)

9 BLOOD SCREENING MARKET, BY REGION

• 9.1 INTRODUCTION
  • TABLE 55 BLOOD SCREENING MARKET, BY REGION, 2021-2028 (USD MILLION)
• 9.2 NORTH AMERICA
  • FIGURE 23 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT
  • TABLE 56 NORTH AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 57 NORTH AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 58 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 59 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 60 NORTH AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 61 NORTH AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 62 NORTH AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 63 NORTH AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2.1 NORTH AMERICA: RECESSION IMPACT
  • 9.2.2 US
    • 9.2.2.1 Increasing prevalence of HIV and chronic diseases to drive market
  • TABLE 64 US: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 65 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 66 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 67 US: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 68 US: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 69 US: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 70 US: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2.3 CANADA
    • 9.2.3.1 Rising volume of surgical procedures to drive market
  • TABLE 71 CANADA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 72 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 73 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 74 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 75 CANADA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 76 CANADA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 77 CANADA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 9.3 EUROPE
  • TABLE 78 EUROPE: BLOOD SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 79 EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 80 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 81 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 82 EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 83 EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 84 EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 85 EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.1 EUROPE: RECESSION IMPACT
  • 9.3.2 GERMANY
    • 9.3.2.1 High incidence of cancer to drive market
  • TABLE 86 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 87 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 88 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 89 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 90 GERMANY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 91 GERMANY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 92 GERMANY: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.3 FRANCE
    • 9.3.3.1 Growing cases of HIV to propel market
  • TABLE 93 FRANCE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 94 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 95 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 96 FRANCE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 97 FRANCE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 98 FRANCE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 99 FRANCE: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.4 UK
    • 9.3.4.1 Favorable government support for infectious disease screening to drive market
  • TABLE 100 UK: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 101 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 102 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 103 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 104 UK: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 105 UK: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 106 UK: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.5 ITALY
    • 9.3.5.1 Growing number of blood donors to support market growth
  • TABLE 107 ITALY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 108 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 109 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 110 ITALY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 111 ITALY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 112 ITALY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 113 ITALY: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.6 SPAIN
    • 9.3.6.1 Rising adoption of NAT technology to propel market
  • TABLE 114 SPAIN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 115 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 116 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 117 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 118 SPAIN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 119 SPAIN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 120 SPAIN: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.7 REST OF EUROPE
  • TABLE 121 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
  • TABLE 122 REST OF EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 123 REST OF EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 124 REST OF EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 125 REST OF EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 126 REST OF EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 127 REST OF EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 128 REST OF EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 9.4 ASIA PACIFIC
  • FIGURE 24 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT
  • TABLE 129 ASIA PACIFIC: BLOOD SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 9.4.2 CHINA
    • 9.4.2.1 High burden of infectious diseases to drive market
  • TABLE 137 CHINA: KEY MACROINDICATORS
  • TABLE 138 CHINA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 139 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 140 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 CHINA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 142 CHINA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 143 CHINA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 144 CHINA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing adoption of advanced blood screening technologies to drive market
  • TABLE 145 JAPAN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 146 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 147 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 148 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 149 JAPAN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 150 JAPAN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 151 JAPAN: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.4 INDIA
    • 9.4.4.1 Increasing road accidents to support market growth
  • TABLE 152 INDIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 153 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 154 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 155 INDIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 156 INDIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 157 INDIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 158 INDIA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing cases of leukemia to drive market
  • TABLE 159 AUSTRALIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 160 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 161 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 162 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 163 AUSTRALIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 164 AUSTRALIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 165 AUSTRALIA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.6 REST OF ASIA PACIFIC
  • TABLE 166 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 167 REST OF ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 168 REST OF ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 169 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 170 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 172 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 9.5 LATIN AMERICA
  • TABLE 173 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 174 LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 175 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 176 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 177 LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 178 LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 179 LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 180 LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.5.1 LATIN AMERICA: RECESSION IMPACT
  • 9.5.2 BRAZIL
    • 9.5.2.1 Growing cancer burden to support market growth
  • TABLE 181 INCIDENCE OF CANCERS IN BRAZIL, 2020 VS. 2025
  • TABLE 182 BRAZIL: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 183 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 184 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 185 BRAZIL: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 186 BRAZIL: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 187 BRAZIL: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 188 BRAZIL: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.5.3 MEXICO
    • 9.5.3.1 Rising blood donations to support market growth
  • TABLE 189 MEXICO: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 190 MEXICO: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 191 MEXICO: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 192 MEXICO: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 193 MEXICO: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 194 MEXICO: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 195 MEXICO: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.5.4 REST OF LATIN AMERICA
  • TABLE 196 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 197 REST OF LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 198 REST OF LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 199 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 200 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 201 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 202 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 RISING SURGICAL PROCEDURES DUE TO CHRONIC DISEASES TO FUEL MARKET
  • TABLE 203 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 204 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 205 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021-2028 (USD MILLION)
  • TABLE 206 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 207 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 208 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021-2028 (USD MILLION)
  • TABLE 209 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 STRATEGIES OF KEY PLAYERS
  • 10.2.1 BLOOD SCREENING MARKET: OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS
  • TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
• 10.3 REVENUE SHARE ANALYSIS
  • FIGURE 25 REVENUE SHARE ANALYSIS OF LEADING PLAYERS IN BLOOD SCREENING MARKET
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 BLOOD SCREENING MARKET
  • FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYER (2022)
  • TABLE 211 BLOOD SCREENING MARKET: INTENSITY OF COMPETITIVE RIVALRY
• 10.5 COMPANY EVALUATION MATRIX
  • 10.5.1 LIST OF EVALUATED VENDORS
  • 10.5.2 STARS
  • 10.5.3 EMERGING LEADERS
  • 10.5.4 PERVASIVE PLAYERS
  • 10.5.5 PARTICIPANTS
  • FIGURE 27 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
• 10.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 STARTING BLOCKS
  • 10.6.3 RESPONSIVE COMPANIES
  • 10.6.4 DYNAMIC COMPANIES
  • FIGURE 28 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
• 10.7 COMPETITIVE BENCHMARKING
  • 10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
  • FIGURE 29 BLOOD SCREENING MARKET: PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
  • TABLE 212 BLOOD SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
  • TABLE 213 BLOOD SCREENING MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT ANALYSIS
  • TABLE 214 BLOOD SCREENING MARKET: COMPANY REGIONAL FOOTPRINT ANALYSIS
  • TABLE 215 BLOOD SCREENING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• 10.8 COMPETITIVE SCENARIO
  • 10.8.1 PRODUCT LAUNCHES
  • TABLE 216 BLOOD SCREENING MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-SEPTEMBER 2023)
  • 10.8.2 DEALS
  • TABLE 217 BLOOD SCREENING MARKET: KEY DEALS (JANUARY 2020-SEPTEMBER 2023)

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 11.1.1 F. HOFFMANN-LA ROCHE LTD.
• TABLE 218 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
• FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
• 11.1.2 GRIFOLS, S.A.
• TABLE 219 GRIFOLS, S.A.: BUSINESS OVERVIEW
• FIGURE 31 GRIFOLS S.A.: COMPANY SNAPSHOT (2022)
• 11.1.3 ABBOTT LABORATORIES
• TABLE 220 ABBOTT LABORATORIES: BUSINESS OVERVIEW
• FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
• 11.1.4 BIO-RAD LABORATORIES, INC.
• TABLE 221 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
• FIGURE 33 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
• 11.1.5 DIASORIN
• TABLE 222 DIASORIN: BUSINESS OVERVIEW
• FIGURE 34 DIASORIN: COMPANY SNAPSHOT (2022)
• 11.1.6 BIOMERIEUX
• TABLE 223 BIOMERIEUX: BUSINESS OVERVIEW
• FIGURE 35 BIOMERIEUX: COMPANY SNAPSHOT (2022)
• 11.1.7 BD
• TABLE 224 BD: BUSINESS OVERVIEW
• FIGURE 36 BD: COMPANY SNAPSHOT (2022)
• 11.1.8 DANAHER (BECKMAN COULTER, INC.)
• TABLE 225 DANAHER: BUSINESS OVERVIEW
• FIGURE 37 DANAHER: COMPANY SNAPSHOT (2022)
• 11.1.9 HOLOGIC, INC.
• TABLE 226 HOLOGIC, INC.: BUSINESS OVERVIEW
• FIGURE 38 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
• 11.1.10 SIEMENS HEALTHINEERS AG
• TABLE 227 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
• FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
• 11.1.11 THERMO FISHER SCIENTIFIC, INC.
• TABLE 228 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
• FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
• 11.2 OTHER PLAYERS
  • 11.2.1 ORTHO CLINICAL DIAGNOSTICS
  • 11.2.2 MERCK KGAA
  • 11.2.3 REVVITY (PART OF PERKINELMER INC.)
  • 11.2.4 BIO-TECHNE
  • 11.2.5 GFE
  • 11.2.6 TRINITY BIOTECH
  • 11.2.7 J. MITRA & CO. PVT. LTD.
  • 11.2.8 MINDRAY
  • 11.2.9 MACCURA BIOTECHNOLOGY CO., LTD.
  • 11.2.10 IMMUCOR, INC.
  • 11.2.11 CELLABS
  • 11.2.12 ABNOVA CORPORATION
  • 11.2.13 ENZO BIOCHEM, INC.
  • 11.2.14 TULIP DIAGNOSTICS PVT. LTD.
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료